Technical Data
ODQ (1H-Oxadiazolequinoxalin-1-one)
Biochemicals Storage: 4C/-20CShipping: Blue Ice
Potent and highly selective, irreversible inhibitor of soluble guanylyl cyclase (sGC). The binding is competitive with nitric oxide (NO). Tool to elucidate the nitric oxide (NO)-cGMP pathway. Apoptosis inhibitor Inhibits growth and migration of prostate cancer cells independent of its effects on GMP levels.

Storage and Stability:
Short-term Storage: +4C
Long-term Storage: -20C
Stable for at least 2 years after receipt when stored at -20C.

CAS Number:

Molecular Formula:

Molecular Weight:
Purity: >98% (NMR)

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Product Reference:
Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylyl cyclase: C.L. Boulton, et al.; Neuroscience 69, 699 (1995)
Novel guanylyl cyclase inhibitor, ODQ reveals role of nitric oxide, but not of cyclic GMP in endothelin-1 secretion: F. Brunner, et al.; FEBS Lett. 376, 262 (1995)
Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-oxadiazoloquinoxalin-1-one: J. Garthwaite, et al.; Mol. Pharmacol. 48, 184 (1995)
Characterization of 1H-oxadiazoloquinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase: A. Schrammel, et al.; Mol. Pharmacol. 50, 1 (1996)
Inhibition of Soluble Guanylate Cyclase by ODQ: Y. Zhao, et al.; Biochemistry 39, 10848 (2000)
cGMP-independent anti-tumour actions of the inhibitor of soluble guanylyl cyclase, ODQ, in prostate cancer cell lines: G. Haramis, et al.; Br. J. Pharmacol. 155, 804 (2008)

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.